Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer: Analysis of the prognostic effect of serum vitamin D on pancreatic cancer: Several confounders.

Autor: Rasmussen LS; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. Electronic address: loskr@rn.dk., Yilmaz MK; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Falkmer UG; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark., Poulsen LØ; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark., Bøgsted M; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Christensen HS; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Bojesen SE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Jensen BV; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Chen IM; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Johansen AZ; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Hansen CP; Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Hasselby JP; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Holländer N; Department of Oncology, Zealand University Hospital, Næstved, Denmark., Nielsen SE; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Oncology and Palliative Care, North Zealand University Hospital, Hillerød, Denmark., Andersen F; Department of Oncology and Palliative Care, North Zealand University Hospital, Hillerød, Denmark., Bjerregaard JK; Department of Oncology, Odense University Hospital, Odense, Denmark., Pfeiffer P; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark., Johansen JS; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Nov; Vol. 158, pp. 248-250. Date of Electronic Publication: 2021 Oct 09.

Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.

Autor: Rasmussen LS; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. Electronic address: loskr@rn.dk., Yilmaz MK; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Falkmer UG; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark., Poulsen LØ; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark., Bøgsted M; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Christensen HS; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Bojesen SE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Jensen BV; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Chen IM; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Johansen AZ; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Hansen CP; Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Hasselby JP; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Holländer N; Department of Oncology, Zealand University Hospital, Næstved, Denmark., Nielsen SE; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Oncology and Palliative Care, North Zealand University Hospital, Hillerød, Denmark., Andersen F; Department of Oncology and Palliative Care, North Zealand University Hospital, Hillerød, Denmark., Bjerregaard JK; Department of Oncology, Odense University Hospital, Odense, Denmark., Pfeiffer P; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark., Johansen JS; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Feb; Vol. 144, pp. 72-80. Date of Electronic Publication: 2020 Dec 17.

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.

Autor: Chen IM; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. Inna.Chen@regionh.dk., Johansen AZ; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Dehlendorff C; Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark., Jensen BV; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Bojesen SE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Bjerregaard JK; Department of Oncology, Odense University Hospital, Odense, Denmark., Nielsen SE; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Department of Oncology, North Zealand University Hospital, Hillerød, Denmark., Andersen F; Department of Oncology, North Zealand University Hospital, Hillerød, Denmark., Holländer NH; Department of Oncology, Zealand University Hospital, Næstved, Denmark., Yilmaz MK; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark., Rasmussen LS; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark., Johansen JS; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Publikováno v: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2020 Jan; Vol. 29 (1), pp. 176-184. Date of Electronic Publication: 2019 Nov 04.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.

Autor: Bastholt L; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark. Electronic address: lars.bastholt@rsyd.dk., Svane IM; Center for Cancer Immune Therapy, Department of Oncology and Haematology, Copenhagen University Hospital, Herlev, Denmark., Bjerregaard JK; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark., Herrstedt J; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark., Hróbjartsson A; Center for Evidence-Based Medicine, University of Southern Denmark, Odense, Denmark., Schmidt H; Department of Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Jul; Vol. 115, pp. 61-67. Date of Electronic Publication: 2019 May 17.

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.

Autor: Winther SB; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark. stine.winther@rsyd.dk.; Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, 3. Sal, 5000, Odense C, Denmark. stine.winther@rsyd.dk., Bjerregaard JK; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Schonnemann KR; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Ejlsmark MW; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Krogh M; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Jensen HA; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Pfeiffer P; Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark.; Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, 3. Sal, 5000, Odense C, Denmark.; Odense Pancreas Center (OPAC), Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2018 Mar; Vol. 81 (3), pp. 573-578. Date of Electronic Publication: 2018 Jan 31.